Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 39288781

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2024 Sep 28
First author
Spicer JD

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2024 Sep 28;404(10459):1176-1178. doi: 10.1016/S0140-6736(24)01920-2.
    note
    Source null
    related pmid
    39288778
    relationship
    Comment in

Authors and identifiers

  1. name
    Spicer JD
    type
    Author
  2. name
    Garassino MC
    type
    Author
  3. name
    Wakelee H
    type
    Author
  4. name
    Liberman M
    type
    Author
  5. name
    Kato T
    type
    Author
  6. name
    Tsuboi M
    type
    Author
  7. name
    Lee SH
    type
    Author
  8. name
    Chen KN
    type
    Author
  9. name
    Dooms C
    type
    Author
  10. name
    Majem M
    type
    Author
  11. name
    Eigendorff E
    type
    Author
  12. name
    Martinengo GL
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Spicer JD
    type
    Author
  2. name
    Garassino MC
    type
    Author
  3. name
    Wakelee H
    type
    Author
  4. name
    Liberman M
    type
    Author
  5. name
    Kato T
    type
    Author
  6. name
    Tsuboi M
    type
    Author
  7. name
    Lee SH
    type
    Author
  8. name
    Chen KN
    type
    Author
  9. name
    Dooms C
    type
    Author
  10. name
    Majem M
    type
    Author
  11. name
    Eigendorff E
    type
    Author
  12. name
    Martinengo GL
    type
    Author
bibliography ids
  1. nci-bib-058d29aa6272ae754db0d59e
book metadata
content sha256
d275b36a2b7510454f56f225cfdad54d6985f7386222ce314b610bfdb275856b
document type
citation
dois
  1. 10.1016/S0140-6736(24)01756-2
electronic publication date
display
2024 Sep 14
precision
day
year
2024
evidence scope
bibliographic_metadata_only
id
pubmed:39288781
immutable id
pubmed:39288781@d275b36a2b7510454f56f225cfdad54d6985f7386222ce314b610bfdb275856b
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
10459
name
Lancet (London, England)
nlm unique id
2985213R
pages
1240-1252
volume
404
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2024 Sep 28;404(10459):1176-1178. doi: 10.1016/S0140-6736(24)01920-2.
    note
    Source null
    related pmid
    39288778
    relationship
    Comment in
outcomes validated
false
pmid
39288781
provenance
batch id
3e43afde6f26fc8df6da
provider
NCBI PubMed ESummary
record sha256
980b4878af30c1b3f6852596e664df89d59c310a6c54d5f3cf54825928ddcb33
response sha256
fa51c3b310a444d84ada833c4cda53c9e4e97161ab5048020b99c51e56e843d2
retrieved at
2026-09-09T23:48:21.145285+00:00
publication date
display
2024 Sep 28
precision
day
year
2024
publication types
  1. Journal Article
  2. Randomized Controlled Trial
  3. Clinical Trial, Phase III
  4. Multicenter Study
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/39288781/
title
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial.

Preserved source evidence · Not medical advice